A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value

Cancer

Volumn 119, Issue 19, 2013, Pages 3454-3461

  Lu, Karen H ^a   Skates, Steven ^b   Hernandez, Mary A ^a   Bedi, Deepak ^a   Bevers, Therese ^a   Leeds, Leroy ^c   Moore, Richard ^d   Granai, Cornelius ^d   Harris, Steven ^e   Newland, William ^f   Adeyinka, Olasunkanmi ^a   Geffen, Jeremy ^g   Deavers, Michael T ^a   Sun, Charlotte C ^a   Horick, Nora ^b   Fritsche, Herbert ^a   Bast, Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c OGA Medical Center   (United States)

^d BROWN UNIVERSITY   (United States)

^e Endocrine Associates of Dallas   (United States)

^f Women's Clinic   (United States)

^g Geffen Cancer Ctr/Res Institute   (United States)

Author keywords

CA125; cancer screening; ovarian cancer screening; positive predictive value; transvaginal ultrasound

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ALGORITHM; ARTICLE; BENIGN TUMOR; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT REFERRAL; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK OF OVARIAN CANCER ALGORITHM; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; UNITED STATES;

CA125; CANCER SCREENING; OVARIAN CANCER SCREENING; POSITIVE PREDICTIVE VALUE; TRANSVAGINAL ULTRASOUND;

AGED; ALGORITHMS; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84884910002     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28183     Document Type: Article

References (7)

1. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995; 76 (10 suppl): 2004-2010.
2. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193: 1630-1639.
3. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. BMJ. 1996; 313: 1355-1358.
4. Skates SJ, Pauler DK, Jacobs IJ,. Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc. 2001; 96: 429-439.
5. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003; 21: 206-210.
6. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005; 23: 7919-7926.
7. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327-340.